Navitas Life Sciences

Optimized Safety and Efficacy Clinical Trials for a Combination Therapy on Moderate COVID-19 Patients

Our client, a multinational mid-sized pharma company headquartered in India needed an end-to-end clinical trial partner to evaluate a randomized, open label, 8-treatment arm clinical trial to evaluate the safety and efficacy of four marketed drugs in the acute treatment of COVID-19 patients.

Read our latest case study and learn how we are driving operational approaches to evaluate the safety and efficacy of their therapies in moderate COVID-19 patients. From being awarded the studies to date we have:

  • Quickly activated sites within 20 days
  • Achieved FPI within 28 days of study award
  • Accomplished 100% on-time completion of key milestones
  • Comprehensive trial oversight through our in-house analytics platform

Please complete the form to download our case study.

Please complete form to download PDF
First Name
Last Name
Business Email
Company
Job Title
Country
By submitting this form, I agree to receive email communications from Navitas Life Sciences. Privacy Policy | EU-US & Swiss-US Privacy Shield Policy

© 2020 Navitas Life Sciences | A TAKE Solutions Enterprise  
Privacy Policy EU-US & Swiss-US Privacy Shield Policy